|
|
Prepublished online as a Blood First Edition Paper on April 10, 2003; DOI 10.1182/blood-2002-09-2866.
 Previous Article | Table of Contents | Next Article 
Blood, 1 August 2003, Vol. 102, No. 3, pp. 1131-1137
TRANSPLANTATION
Hematopoietic stem cell transplantation: contrasting the outcome of transplantations from HLA-identical siblings, partially HLA-mismatched related donors, and HLA-matched unrelated donors
Hellmut D. Ottinger,
Stanislav Ferencik,
Dietrich W. Beelen,
Monika Lindemann,
Rudolf Peceny,
Ahmed H. Elmaagacli,
Johannes Hüsing, and
Hans Grosse-Wilde
From the Department of Bone Marrow Transplantation, Institute of Immunology and Institute for Medical Informatics, Biometry and Epidemiology, University Hospital of Essen, Germany
Allogeneic hematopoietic stem cell transplantation (HSCT) is a proven curative therapy for many hematologic malignancies. HSCT from HLA-identical sibling donors (ISDs) is still the golden standard. For the remaining 70% of the patients lacking an ISD, alternative (partially) HLA-matched family donors (MFDs) and HLA-matched unrelated donors (MUDs) are now widely accepted. However, it is presently unclear whether outcome after HSCT from an MFD or an MUD is superior. Thus, the classical clinical end points after HSCT from an ISD (n = 138), MFD (n = 86), and MUD (n = 101) were compared by means of univariate and multivariate statistical analyses. MFD transplantations with HLA class II (DRB1 ± DQB1) mismatches in graft-versus-host (GVH) direction showed an increased risk of grades II to IV graft-versus-host disease, and MFD transplantations with more than a single HLA class I (A ± B ± C) mismatch in host-versus-graft (HVG) direction were associated with a higher risk of graft failure. However, no significant difference in overall survival was detectable among the 3 study groups after adjustment for the main predictors of transplantation outcome. Thus, for patients lacking an ISD, an already identified MFD with an HLA-DRB1 ± DQB1 mismatch in GVH or a combined HLA-A ± B ± C mismatch in HVG direction should be accepted only in clinically urgent settings that leave no time to identify an MUD.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
H. Xiao-Jun, X. Lan-Ping, L. Kai-Yan, L. Dai-Hong, W. Yu, C. Huan, C. Yu-Hong, H. Wei, W. Jing-Zhi, C. Yao, et al.
Partially Matched Related Donor Transplantation Can Achieve Outcomes Comparable with Unrelated Donor Transplantation for Patients with Hematologic Malignancies
Clin. Cancer Res.,
July 15, 2009;
15(14):
4777 - 4783.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Schetelig, M. Bornhauser, C. Schmid, B. Hertenstein, R. Schwerdtfeger, H. Martin, M. Stelljes, U. Hegenbart, K. Schafer-Eckart, M. Fussel, et al.
Matched Unrelated or Matched Sibling Donors Result in Comparable Survival After Allogeneic Stem-Cell Transplantation in Elderly Patients With Acute Myeloid Leukemia: A Report From the Cooperative German Transplant Study Group
J. Clin. Oncol.,
November 10, 2008;
26(32):
5183 - 5191.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ditschkowski, A. H. Elmaagacli, R. Trenschel, R. Peceny, M. Koldehoff, C. Schulte, and D. W. Beelen
T-cell depletion prevents from bronchiolitis obliterans and bronchiolitis obliterans with organizing pneumonia after allogeneic hematopoietic stem cell transplantation with related donors
Haematologica,
April 1, 2007;
92(4):
558 - 561.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Fischer, H. Ottinger, S. Ferencik, M. Sribar, M. Punzel, D. W. Beelen, M. A. Schwan, H. Grosse-Wilde, P. Wernet, and M. Uhrberg
Relevance of C1 and C2 Epitopes for Hemopoietic Stem Cell Transplantation: Role for Sequential Acquisition of HLA-C-Specific Inhibitory Killer Ig-Like Receptor
J. Immunol.,
March 15, 2007;
178(6):
3918 - 3923.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Takahashi, J. Ooi, A. Tomonari, T. Konuma, N. Tsukada, M. Oiwa-Monna, K. Fukuno, M. Uchiyama, K. Takasugi, T. Iseki, et al.
Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen
Blood,
February 1, 2007;
109(3):
1322 - 1330.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Yakoub-Agha, F. Mesnil, M. Kuentz, J. M. Boiron, N. Ifrah, N. Milpied, S. Chehata, H. Esperou, J.-P. Vernant, M. Michallet, et al.
Allogeneic Marrow Stem-Cell Transplantation From Human Leukocyte Antigen-Identical Siblings Versus Human Leukocyte Antigen-Allelic-Matched Unrelated Donors (10/10) in Patients With Standard-Risk Hematologic Malignancy: A Prospective Study From the French Society of Bone Marrow Transplantation and Cell Therapy
J. Clin. Oncol.,
December 20, 2006;
24(36):
5695 - 5702.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. W. Beelen, H. D. Ottinger, S. Ferencik, A. H. Elmaagacli, R. Peceny, R. Trenschel, and H. Grosse-Wilde
Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias
Blood,
March 15, 2005;
105(6):
2594 - 2600.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
